Best Life Sciences Platforms and Tools Companies in New South Wales, Australia
The 31 best Life Sciences Platforms and Tools companies in New South Wales, Australia in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: Inventia Life Science.
Our analysis of 50 Life Sciences Platforms and Tools companies
$4.8b in tracked funding; 68% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
Ranked: Best Life Sciences Platforms and Tools companies in New South Wales
| # | Company | Disclosed funding | Last round | Stage | Founder | Founded | Tech stack | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Inventia Life Science Developer of 3D bio-printers | $50M | 53 mo ago | Series B | Aidan O'Mahony Co-Founder & CTO | 2013 | HubSpot CMS HubApple iCloud MailMicrosoft 365+19 | 43 patents 3D bioprinting hardware and detachable printheads for tissue engineering constructs | — |
| 2 | Elastagen Company offering solutions for cell growth and tissue repair through their Elastin technology | $15M | 121 mo ago | Acquired | — | 2003 | — | — | — |
| 3 | Genetic Signatures Molecular diagnostic reagents and kits for pathogen detection | $11M | 122 mo ago | Public | — | 2001 | WordPressApple iCloud MailMySQL+26 | 165 patents Isothermal nucleic acid amplification and microbial DNA preparation for rapid molecular diagnostics | — |
| 4 | Vectus Biosystems Develops drug discovery platform | $2M | 47 mo ago | Public | Karen Duggan Founder & CEO | 2005 | — | 257 patents Small-molecule anti-fibrotic therapeutics for kidney, liver, lung and hypertension | — |
| 5 | Solvanix Provides technology for improving stability and reducing the aggregation of fully human antibodies | $2M | 141 mo ago | Deadpooled | Daniel Christ Founder & CSO | 2015 | — | — | — |
| 6 | Absolute Bioscience Laboratory Reagents, Laboratory Consumables, and Laboratory Equipments | — | — | Deadpooled | Guangjin Lu CEO & Director | 2016 | — | — | — |
| 7 | AgriGen Provider of DNA testing for food, agriculture, and environmental applications | — | — | Unfunded | Ross Brierty CEO | 2004 | — | — | — |
| 8 | Anthrocell Developer of monoclonal antibodies and recombinant proteins | — | — | Funding Raised | Galina Kaseko Co-Founder & CEO | 2010 | — | — | — |
Top 5 Life Sciences Platforms and Tools companies in New South Wales
#1
Series B · Sydney, New South Wales · founded 2013 · 90 employees$50Mraised▾
Operator of a bioprinting platform intended to help accelerate cancer research, drug discovery, and develop regenerative medicine. The company's digital 3D bioprinting technology allows rapid fabrication of living biological structures to accelerate the discovery of drugs for cancer and other diseases, enabling biomedical companies with an efficient bioprinting tool of 3D cell-based assays for research.
#2
Public · Rosebery, New South Wales · founded 2005$2Mraised▾
Vectus Biosystems has developed a platform technology for drug discovery and development. It has constructed a library of more than 200 small molecules with varying degrees of anti-hypertensive and/or anti-fibrotic properties. Additionally, the company's wholly-owned subsidiary, Accugen Pty Limited has designed and developed Accugen, a platform comprising of reagents and software that quantify qPCR reactions. It also holds patents around the Vasoactive Intestinal Peptide (VIP) and its fragments as a therapeutic candidate to treat cardiovascular fibrosis and systolic blood pressure. Vectus licenses its technology and intends to remain a research and development company.
- Nov 2022Post IPO$2M
#3
Acquired · Sydney, New South Wales · founded 2003 · 5 employees$14.7Mraised▾
Elastagen is a clinical stage medical company with a pipeline of formulation products based on the human protein tropoelastin.The company was founded after the acquisition of the Elastin technology from its founding scientist Prof Weiss (who is also the company's Lead Scientific Advisor) and his team at the University of Sydney. The Elastin technology offers a new pathway to produce a synthetic, identical and recombinant version of the naturally found "tropoelastin", the building blocks of elastin, a critical component in tissues responsible for the ability of lungs, skin, arteries and other elastic ligaments to stretch and recoil. The company claims that it is the first and only provider of commercial cGMP clinical grade human tropoelastin which can be used to support cell growth and tissue repair. Elastagen also claims the recombinant tropoelastin has an ideal biocompatibility profile and no immune rejection problems. Currently, the company is conducting pivotal clinical studies an injectable dermo-aesthetic product that supposedly restores the elasticity of the skin. In addition, it is investigating solutions for Atrophic Scars, Scar Revision and wound healing. Elastagen claims
- Oct 2016Grant (prize money)$4M
- Jun 2016Series B$744.8K
- Jan 2016Series B$9.2M
- Jul 2013Grant (prize money)$2M
#4
Public · Darlinghurst, New South Wales · founded 2001$10.7Mraised▾
Genetic Signatures develops and markets diagnostic reagents and kits for pathogen detection. Its proprietary 3Base technology uses the bisulfite method to enable pathogen detection by differentiating between methylated and unmethylated cytosine residues. Its flagship range of products EaasyScreen allows for the easy multiplexing of tests and is applicable for both DNA and RNA.
- Sep 2016Post IPO$10.7M
#5
Deadpooled · Darlinghurst, New South Wales · founded 2015$1.6Mraised▾
Solvanix provides technology for improving stability and reducing the aggregation of fully human antibodies. It provides StAbilize, which works by boosting stability and reducing aggregation of monoclonal antibodies, antibody fragments, and bi-specifics. The company works with biotech and pharma industries developing therapeutic antibodies by providing human binding domain sequences. It also provides commercial licenses and non-exclusive licenses.
- Jan 2015Seed$1.6M
Funding & investor landscape
Notable founders
Market landscape — 10 sub-themes by coverage
Share of Life Sciences Platforms and Tools coverage by sub-theme.
Regulatory-risk over time rising
Funding & growth over time
funding rising · growth rising
How research on Bioinformatics is moving in Australia
A read on the academic research around Bioinformatics — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 1,442 Australia-affiliated papers.
- University College London180
- Monash University103
- The University of Melbourne89
- The University of Queensland89
- The University of Sydney80
- Gene8→45
- Genome12→45
- Transcriptome2→34
- Identification (biology)2→19
- Immune system1→18
- Disease3→52
- Transcriptome1→21
- Gene2→21
- Biomarker1→20
- Cancer3→21
- Disease4→53
- Identification (biology)1→12
- Genome1→12
- Genomics1→10
- Diabetes mellitus3→11
Where bioinformatics is researched across Australia
Location clusters by institution affiliation — each city's volume, stance tone, and a quick read on its hot topic, what's advancing, the opening opportunity, and the main concern.
Common questions
Rohit lives in the feed. He covers what's moving right now — the funding rounds, launches and shifts breaking across the trade press — and ties them back to where the sector is heading.